Page 146 - CW E-Magazine (22-10-2024)

Pharmaceuticals

CONTRACT MANUFACTURING
Strides launches speciality pharma CDMO, OneSource

OneSource Specialty Pharma, a security, and serves as a tailwind to the
newly incorporated Contract Develop- CDMO’s ambitious growth plans.
ment and Manufacturing Organisation
(CDMO), formed from the merger of Mr. Neeraj Sharma, CEO of One-
three CDMO businesses within the Source, stated, “As demand for innova-
Bangalore-based Strides Group was tive CDMO solutions grows, especially
launched at the recently held CPHI for complex therapies, we are well-
Milan – an annual pharma industry positioned to accelerate drug develop-
exhibition. The company has a 30-year ment and manufacturing for our global
track-record in biologics, drug-device The three combined businesses, partners.”
combinations, and soft gelatin capsules. each serve over 50 global clients, and
together reduce complexity, cost, and Strides Pharma had sought share-
The newly combined CDMO has resources associated with managing holder approval for a scheme of arrange-
fi ve facilities approved by major regu- multiple CDMO service providers. ment among the company, Steriscience
latory agencies, including the US FDA, Specialties Pvt. Ltd. and Onesource
EU, and TGA, with a workforce of OneSource is projected to achieve Specialty Pvt. Ltd. (earlier known as
over 1,200. OneSource has capabilities 32% revenue growth in 2025, with Stelis Biopharma). As part of the
spanning supply-constrained drug-de- sales anticipated to reach $400-mn by scheme, Strides Pharma and Steri-
vice combinations, biologics, and soft 2028. The company’s strong growth science’s identifi ed CDMO business,
gelatin capsules – with the capacity prospects are driven by industry trends, along with Strides Pharma’ soft gelatine
to produce more than 100-mn inject- including the increasing self-adminis- business, would be consolidated under
able doses including cartridges and tration of drugs via auto-injectors, led Onesource.
pre-fi lled-syringes and 2.4-bn soft gela- by signifi cant success of GLP-1 medi-
tin capsules. Its fl agship site in Banga- cations. In addition, the US Biosecure OneSource is currently undergoing
lore is one of the few globally capable Act is continuing to drive signifi cant regulatory approvals and, upon com-
of manufacturing both biologics and interest as pharma partners look to pletion, will be listed on Indian stock
drug product on the same premises. increase supply chain diversity and exchanges.

CII PHARMA & LIFE SCIENCES SUMMIT
Pharma exports surge amid global slowdown: DoP Secretary

In a signifi cant development for exports have experienced double-digit developed primarily by Indian com-
India’s pharmaceutical and medical growth over the past year. In the fi rst panies utilising incentives from the
technology sectors, export growth is four months of the current year, these Production Linked Incentive (PLI)
expected to remain robust in the current exports have become the fourth largest scheme. The Drugs Controller General
fi scal year, despite global economic merchandise export item for the Indian of India (DCGI), he added, has already
headwinds. This was revealed by a economy, marking a signifi cant mile- granted approvals for some of these
senior government offi cial during the ‘CII stone for the sector. molecules.
Pharma and Life Sciences Summit’
held in New Delhi on October 9, 2024. Mr. Chawla revealed that recent The government is also focusing on
patent cliff studies have identifi ed 26 developing upstream value chains for
Mr. Arunish Chawla, Secretary, blockbuster molecules, with 16 cur- biological entities, including basic mole-
Department of Pharmaceuticals (DoP), rently in various stages of approvals cules like amino acids, nucleotides,
highlighted the recent export trends, and manufacturing licences. These and vaccine raw materials. These initi-
noting that despite a general slow- molecules, comprising both small and atives are expected to further bolster
down in global exports, Indian pharma- large molecules, are targeted at major India’s position in the global pharma-
ceuticals, biotech, and bulk drug therapeutic segments and are being ceutical and medical technology mar-

146 Chemical Weekly October 22, 2024

Contents Index to Advertisers Index to Products Advertised